|
Without comprehensive biomarker testing, patients with metastatic non–small cell lung cancer (NSCLC) who are candidates for targeted therapy could be missed. Therapies that don’t target active oncogenic drivers can translate into worse outcomes, including lower overall survival rates.1,2
|
|
|
| |
|
The NCCN NSCLC Panel recommends molecular testing for actionable biomarkers and strongly advises broad molecular profiling—such as next-generation sequencing (NGS)—to identify rare driver mutations in eligible patients with metastatic NSCLC for which effective drugs may already be available.3
|
|
|
|
References: 1. Barlesi F, Mazieres J, Merlio JP, et al. Routine molecular profiling of cancer: results of a one-year nationwide program of the
French Cooperative Thoracic Intergroup (IFCT) for advanced non-small cell lung cancer (NSCLC) patients. Lancet. 2016;287(10026):1415-1426.
2. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998-2006.
3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.2.2020.
© National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed January 7, 2020. To view the most recent and complete version of the guideline,
go online to NCCN.org.
|
|
NCCN=National Comprehensive Cancer Network®.
|
|
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
|
